Global Generic Drugs Market Research, Share, Size and Forecast 2017-2022

1

Generic Drugs Market Global Industry Trends,
Manufacturing Process, Share, Size, Growth,
Opportunity and Forecast 2017-2022
Copyright IMARC. All Rights Reserved
2
About IMARC Group
Report Description
IMARC is a leading advisor on management
strategy and market research worldwide. We
partner with clients in all sectors and regions
to identify their highest-value opportunities,
address their most critical challenges, and
transform their businesses. IMARCs information
products include major market, scientific,
economic and technological developments for
business leaders in pharmaceutical, industrial,
and high technology organizations. Market
forecasts and industry analysis for
biotechnology, advanced materials,
pharmaceuticals, food and beverage, travel and
tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
Global Generic Drugs Market Catalysed by Low
Investments in RD and Government
Initiatives The global generic drugs market has
witnessed a rapid growth in recent years. Some of
the factors which have helped in the market
growth of generic drugs are their performance
characteristics, cost-effectiveness, reduced
investments in RD, patent expiry of the branded
drugs, etc. The latest report by IMARC Group
titled, Generic Drugs Market Global Industry
Trends, Manufacturing Process, Share, Size,
Growth, Opportunity and Forecast 2017-2022,
finds that the global generic drugs
market reached a value of nearly US 230 Billion
in 2016, growing at a CAGR of more than 7 during
2010-2016. Generic drugs have the same active
ingredients and possess similar performance
characteristics as their branded variants, such
as strength, quality, form, effect, intended use,
side effects, route of administration,
therapeutic effect, etc. These drugs are
manufactured under the same rules and regulations
of manufacturing practices required for branded
drugs. However, they are sold under their
chemical names rather than the brand names. Read
full report _at_ http//www.imarcgroup.com/generic-dr
ug-manufacturing-plant
4
Report Description and Highlights
Report Description

• Highlights of the global generic drugs market
• The market is driven primarily by their
  affordability.
• The USA represents the largest market for these
  drugs, accounting for the majority of the share.
• The market is expected to reach a value of around
  US 360 Billion by 2022.
• The cost-effectiveness of the generic drugs has
  emerged as one of the major factors which has
  contributed in influencing the growth of the
  market. These drugs require low investments in
  research development, which brings down the
  cost of manufacturing significantly. This has
  encouraged the government and third-party payers
  to promote the manufacturing of these drugs and
  save billions of dollars on healthcare
  expenditures. Apart from this, the patent expiry
  of the branded drugs is also an essential factor
  which provides encouragement to the generic drugs
  market. Most branded drugs come with a lifespan
  of 20 years during which other manufacturers
  cannot sell the branded drugs under their
  companies name. However, when the patent
  protection expires, the manufacturing rights of
  these drugs is available to the other
  manufacturers. Some of the other growth inducing
  factors include rising aging-population,
  increasing prevalence of chronic diseases, and
  incentives offered to physicians and pharmacists
  to promote generics. Further, the market is
  expected to reach a value of nearly US 360
  Billion by 2022.
• Request Sample of the Report
• http//www.imarcgroup.com/request?typereportid5
  49flagB

5
Report Description and Highlights
Report Description

6
Report Description and Highlights
Report Description

• The report has segmented the market on a regional
  basis. Some of the major markets for generic
  drugs include USA, China, Brazil, Germany and
  France. Amongst these, USA is the largest market,
  accounting for the majority of the share. An
  analysis of the competitive landscape provides
  the details of the key players operative in the
  market. Some of the major players are Teva
  Pharmaceuticals, NovartisSandoz, Mylan,
  Freseunis, and Hospira.
• The report has examined the global generic drugs
  market on the basis of
• Key Regions
• USA
• China
• Brazil
• Germany
• France
• Key Players
• Teva Pharmaceuticals
• Novartis - Sandoz
• Mylan
• Freseunis
• Hospira

7
Report Description and Highlights
Report Description
Related Reports   Brazil Generic Drug Market _at_
http//www.imarcgroup.com/brazil-generic-drug-mark
et US Generic Drug Market _at_ http//www.imarcgroup
.com/us-generics-market
8
Report Description and Highlights
Report Description

2017 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
9

Contact Us